Genprex Inc
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing pla… Read more
Genprex Inc (GNPX) - Total Liabilities
Latest total liabilities as of September 2025: $2.79 Million USD
Based on the latest financial reports, Genprex Inc (GNPX) has total liabilities worth $2.79 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genprex Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how Genprex Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Genprex Inc Competitors by Total Liabilities
The table below lists competitors of Genprex Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aben Gold Corp.
F:ML1
|
Germany | €333.13K |
|
VIP Gloves Ltd
AU:VIP
|
Australia | AU$7.64 Million |
|
Greiffenberger AG
F:GRF
|
Germany | €31.02 Million |
|
LEGRAND
MU:LRC
|
Germany | €8.34 Billion |
|
TronicS Microsystems SA
PA:ALTRO
|
France | €17.73 Million |
|
YUM BRANDS - Dusseldorf Stock Exchang
DU:TGR
|
Germany | €14.13 Billion |
|
Genix Pharmaceuticals Corporation
OTCQB:GENPF
|
USA | $1.35 Million |
|
Retail Food Group Limited
PINK:RFGPF
|
USA | $155.39 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Genprex Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genprex Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genprex Inc (2015–2024)
The table below shows the annual total liabilities of Genprex Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.50 Million | -23.05% |
| 2023-12-31 | $3.25 Million | +15.80% |
| 2022-12-31 | $2.81 Million | +77.27% |
| 2021-12-31 | $1.59 Million | +251.72% |
| 2020-12-31 | $450.72K | -11.74% |
| 2019-12-31 | $510.68K | +31.68% |
| 2018-12-31 | $387.82K | -53.33% |
| 2017-12-31 | $830.96K | +190.89% |
| 2016-12-31 | $285.66K | +1646.73% |
| 2015-12-31 | $16.35K | -- |